Formulation of ciprofloxacin hydrochloride loaded biodegradable nanoparticles: Optimization of the formulation variables.

Authors

  • Salwa Mohamed Salah Lecturer at faculty of pharmacy, cairo university, Egypt

Abstract

The aim of this work was to formulate nanoparticles with longer sustainment since it can play an important role in treatment of chronic osteomyelitis. A factorial design 23 was used to optimize the formulation variables of ciprofloxacin hydrochloride (CP) loaded biodegradable nanoparticles (NPS). The effect of three independent variables, namely; the polymer type  (Poly D, L-lactide-co-glycolide 50/50& Poly (D, L-lactide), the polymer molecular weight(M.Wt) and the drug to polymer ratio on the particle size, encapsulation efficiency (EE%), zeta potential and the time required for 90% of ciprofloxacin to be released (t90%) was investigated . The selected drug loaded nanoparticles was subjected to further investigations including; Scanning electron microscope (SEM), DSC, x-ray powder diffractometry and FTIR spectroscopy. Moreover the antimicrobial effectiveness of the selected formula was investigated.

 The results revealed that The mean particle size e ranged from 180-355 nm while the EE% ranged from 52-70%.  The selected formula retained its antimicrobial activity throughout the preparation process.

Downloads

Published

2013-11-28

How to Cite

Salah, S. M. (2013). Formulation of ciprofloxacin hydrochloride loaded biodegradable nanoparticles: Optimization of the formulation variables. Journal of Pharmaceutical Research and Opinion, 3(11). Retrieved from http://innovativejournal.in/index.php/jpro/article/view/530

Issue

Vol. 3 No. 11 (2013): JOURNAL OF PHARMACEUTICAL RESEARCH AND OPINION

Section

Articles

License

“I ……………………………………….certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (wherever applicable), as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither has the manuscript nor one with substantially similar content under my authorship been published nor is being considered for publication elsewhere, except as described in an attachment. Furthermore I attest that I shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested.”